Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent … (NCT07625306) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
240 participantsStarted 2026-08-31
Plain-language summary
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Who can participate
Age range
18 Years – 79 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Lp(a) ≥ 150 nmol/L
* Within 10 days of hospitalization for ACS event and meets all of the following criteria:
* Clinical syndrome consistent with spontaneous cardiac ischemia
* Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
Exclusion Criteria:
* Uncontrolled hypertension
* Heart failure New York Heart Association (NYHA) class IV
* History of malignancy of any organs
* History of hemorrhagic stroke or other major bleeding
* Platelet count ≤ LLN
* Active liver disease or hepatic dysfunction
* Significant kidney disease
* Contraindication for CCTA or severe contrast allergy
* Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically for people who've had a recent heart attack and have elevated Lp(a) — does my Lp(a) level qualify as 'elevated' by the study's standards, and was my event recent enough to potentially be considered?
2Since this is a Phase 3 trial, what does that mean for what's already known about pelacarsen's safety compared to earlier phases, and are there still unknowns I should weigh before discussing participation with you?
3The trial isn't recruiting yet — how would that affect the timing of my treatment decisions, and should I be pursuing standard-of-care options now while we wait to see if this opens?
4The main thing this study is measuring is how much pelacarsen lowers Lp(a) levels in my blood — do you think getting my Lp(a) down is a meaningful priority in my specific situation, or are there other risk factors we should address first?
5Are there already approved treatments or other studies targeting high Lp(a) after a heart attack that I should be comparing this trial against before deciding whether it's worth discussing further?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.